Genexine Seeks China Entry Through Multi-Biologic Tasly Tie-Up
This article was originally published in PharmAsia News
Executive Summary
South Korean biotech firm Genexine is broadening its presence in Asia. Following an agreement earlier this month with Kalbe Farma to set up a joint venture in Indonesia, it has now signed a licensing out deal for protein therapies with a subsidiary of China’s Tasly Pharmaceutical.
You may also be interested in...
Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum
Genexine has reached a critical point in developing its immuno-oncology pipeline, firming up a $548m-plus licensing out pact for an asset with the Shanghai-based I-Mab Biopharma. The South Korean firm expects the deal to serve as a yardstick of ‘value determination’ in its future global transactions.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.